What the FDA labels say about taking them together
Adalimumab and adalimumab-fkjp
Adalimumab-fkjp's FDA label of January 12, 2026 names adalimumab in its boxed warning section; the adalimumab labels PlainMeds reads (4) do not name adalimumab-fkjp. The adalimumab-fkjp label: “Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either Adalimumab-fkjp or MTX.”
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); the adalimumab-fkjp FDA label on DailyMed (effective January 12, 2026, Biocon Biologics Inc).
What does the adalimumab label say about adalimumab-fkjp?
Adalimumab's label (effective October 21, 2025) and its 3 other brand-application labels do not name adalimumab-fkjp in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
What does the adalimumab-fkjp label say about adalimumab?
Adalimumab-fkjp label, boxed warningSERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products including Adalimumab-fkjp are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) ].
Adalimumab-fkjp label, drug interactionsAlthough MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either Adalimumab-fkjp or MTX [see Clinical Pharmacology (12.3) ].
Adalimumab-fkjp label, warnings and precautionsPatients treated with adalimumab products including Adalimumab-fkjp are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.
Source: FDA drug label (Adalimumab), BLA761154 (Mylan Pharms Inc), as published by Biocon Biologics Inc, effective January 12, 2026 (SPL set 5cde907d-6747-0e62-db25-1718ee717fe7), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Adalimumab | Adalimumab-fkjp | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1,587.82 per mL 40 mg/0.4 mL | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once